genOway Chosen by Tufts University for Major Framework Contract
News Dec 28, 2009
genOway reports an important framework agreement with the Tufts University (Boston, USA).
Following an international competition, the company has been selected for a framework contract for a two years renewable period.
Under the terms of the agreement, researchers at the Tufts University, whose prestigious areas of study cover oncology, cardiovascular disease and virology (especially AIDS), will benefit from the expertise gained by genOway in transgenic technologies and technological innovations developed by the company, such as inducible systems that secure and accelerate the development of sophisticated genetically modified mouse and rat models.
The financial terms of the agreement were not disclosed.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.